JAMESBURG, N.J., Aug. 16, 2007 (PRIME NEWSWIRE) -- The BioAnalytics Group www.bioanalyticsgroup.com has signed a new agreement with Prescient Medical, Inc, of Doylestown, PA, www.prescientmedical.com. The accord addresses development projects in support of Prescient's technologies for preventing and treating heart attacks.
"Since we started working together some months ago, the relationship has been highly professional, with integrity," said Joan M. Lind, Prescient's Vice President for Clinical Affairs. "Our collaboration has been effective in moving Prescient's business forward." The new accord extends a previous agreement and builds on successful milestones.
Prescient Medical, founded in 2004, is dedicated to becoming the leader in pioneering innovative technologies that help reduce patient suffering and death from heart attacks. Among its initiatives are a diagnostic tool and a therapeutic product for patients with cardiovascular disease.
The BioAnalytics Group is employing its Model Based Assay(tm) (MBA) methodologies to calibrate and optimize performance in Prescient's new diagnostic system for characterizing vulnerable plaque. The Raman spectroscopy-based clinical instrument will provide physicians with valuable insight into heart disease which may guide treatment decisions. The MBA is a systematic approach to experimental design that leverages The BioAnalytics Group's depth of knowledge in biomedical modeling and simulation.
The BioAnalytics Group is providing statistical analysis to support Prescient's therapeutic product development. The company is primarily focused on supporting experimental design for upcoming animal studies and human clinical trials. "Prescient has an experienced in-house modeling and analysis team," says G. Scott Lett, Ph.D, CEO of The BioAnalytics Group. "By modeling a specific population of results, and working closely, we can help Prescient design studies that maximize the value of the data collected. This way, we are able to help them get where they're going faster."
In today's device development market, with growing significance in the field of vulnerable plaque, such a competitive edge can be decisive. "By bringing in The BioAnalytics Group, we have enhanced our development process and our ability to reach milestones that keep our new products progressing," says Lind. "In addition to providing significant technical services, Dr. Lett and his team are in alignment with our business goals and our aggressive targets."
The BioAnalytics Group LLC, founded in 2003, offers software products and services in the areas of assay data analysis, data management, biological modeling, technology evaluation, intellectual property evaluation and custom software development. Current customers include wet-lab and computational biology researchers in pharmaceutical companies, laboratory instrumentation and medical device companies, and academic research groups.